Novel thrombolytic agents
暂无分享,去创建一个
[1] D. Behnke,et al. Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase — a bacterial plasminogen activator , 1987, Molecular and General Genetics MGG.
[2] T. Sako,et al. Cloning and expression of the staphylokinase gene of Staphylococcus aureus in Escherichia coli , 2004, Molecular and General Genetics MGG.
[3] H.,et al. A Monoclonal Antibody Specific for Two-Chain Urokinase-Type Plasminogen Activator . Application to the Study of the Mechanism of Clot Lysis With Single-Chain Urokinase-Type Plasminogen Activator in Plasma , 2003 .
[4] U. Tebbe,et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). , 1994, Journal of the American College of Cardiology.
[5] P. Declerck,et al. Prevalence and Induction of Circulating Antibodies against Recombinant Staphylokinase , 1994, Thrombosis and Haemostasis.
[6] D. Collen,et al. Coronary thrombolysis with K1K2PU, a chimeric tissue‐type and urokinase‐type plasminogen activator: A feasibility study in six patients with acute myocardial infarction , 1993, Coronary artery disease.
[7] Stefan Fischer,et al. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis. , 1993, Journal of the American College of Cardiology.
[8] B. Keyt,et al. A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by Bolus, Has Increased Potency and Decreased Systemic Activation of Plasminogen , 1993, Thrombosis and Haemostasis.
[9] K. Silence,et al. Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin. , 1993, The Journal of biological chemistry.
[10] Y. Engelborghs,et al. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. , 1993, The Journal of biological chemistry.
[11] F. Van de Werf,et al. Coronary Thrombolysis With Recombinant Staphylokinase in Patients With Evolving Myocardial Infarction , 1993, Circulation.
[12] D. Collen,et al. Comparative Immunogenicit and Thrombolytic Properties Toward Arterial and Venous Thrombi of Streptokinase and Recombinant Staphylokinase in Baboons , 1993, Circulation.
[13] P. Declerck,et al. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase , 1992 .
[14] P. Marynen,et al. Primary Structure and Gene Structure of Staphylokinase , 1992 .
[15] D. Collen,et al. Biochemical-properties of natural and recombinant staphylokinase , 1992 .
[16] W. Nichols,et al. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator. , 1992, Journal of the American College of Cardiology.
[17] K. Strein,et al. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[18] W. Schleuning,et al. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. , 1992, Blood.
[19] K. Strein,et al. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. , 1992, Journal of the American College of Cardiology.
[20] J. Lynch,et al. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[21] O. Matsuo,et al. On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin-formula> and fibrin , 1992 .
[22] K. Strein,et al. Pharmacokinetics of the Novel Recombinant Plasminogen Activator BM 06.022 in Rats, Dogs, and Non-human Primates , 1992 .
[23] O. Matsuo,et al. Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro , 1992 .
[24] C. Kawai. Multicenter trial of a novel modified t-PA, E6010, by i.v.bolus injection in patients with acute myocardial infarction. , 1992 .
[25] R. Rudolph,et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. , 1992, Protein engineering.
[26] J. D. Frank,et al. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis. , 1992, The Journal of pharmacology and experimental therapeutics.
[27] M. Scully. PLASMINOGEN ACTIVATOR‐DEPENDENT PERICELLULAR PROTEOLYSIS , 1991, British journal of haematology.
[28] G. Agnelli,et al. Thrombus resistance to lysis and reocclusion after thrombolysis: the role of platelets. , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[29] K. Okada,et al. Comparative Fibrinolytic Properties of Staphylokinase and Streptokinase in Animal Models of Venous Thrombosis , 1991, Thrombosis and Haemostasis.
[30] B. Kaufmann,et al. Dose‐ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers , 1991, Clinical pharmacology and therapeutics.
[31] L. Nelles,et al. Thrombolytic and Pharmacokinetic Properties of Chimeric Tissue‐Type and Urokinase‐Type Plasminogen Activators , 1991, Circulation.
[32] D. Collen,et al. Strategies for the Improvement of Thrombolytic Agents , 1991, Thrombosis and Haemostasis.
[33] R. Rudolph,et al. Coronary Thrombolytic Properties of a Novel Recombinant Plasminogen Activator (BM 06.022) in a Canine Model , 1991, Journal of cardiovascular pharmacology.
[34] B. Binder,et al. Function of Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.
[35] D. Collen,et al. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model. , 1991, Blood.
[36] S. Gardell,et al. Effective Thrombolysis Without Marked Plasminemia After Bolus Intravenous Administration of Vampire Bat Salivary Plasminogen Activator in Rabbits , 1991, Circulation.
[37] K. Okada,et al. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. , 1991, The Journal of biological chemistry.
[38] R. Rudolph,et al. Thrombolysis with an Escherichia coli-Produced Recombinant Plasminogen Activator (BM 06.022) in the Rabbit Model of Jugular Vein Thrombosis , 1991, Thrombosis and Haemostasis.
[39] K. Okada,et al. Thrombolytic properties of staphylokinase. , 1990, Blood.
[40] L. Nelles,et al. Characterization of Domain Deletion and/or Duplication Mutants of a Recombinant Chimera of Tissue-Type Plasminogen Activator and Urokinase-Type Plasminogen Activator (rt-PA/u-PAI) , 1990, Thrombosis and Haemostasis.
[41] L. Poller. Anticoagulant therapy with minidose warfarin: present results and possible implications , 1990 .
[42] T. Quertermous,et al. Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1. , 1989, Journal of immunology.
[43] O. Matsuo,et al. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor. , 1989, Biochemical and biophysical research communications.
[44] T. Podor,et al. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. , 1989, The Journal of biological chemistry.
[45] D. Collen,et al. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. , 1989, Blood.
[46] A. Corti,et al. Production and characterisation of human recombinant single chain urokinase-type plasminogen activator from mouse cells , 1989 .
[47] M. Scully,et al. Activation of pro-urokinase by plasmin: non-Michaelian kinetics indicates a mechanism of negative cooperativity. , 1989, Archives of biochemistry and biophysics.
[48] L. Nelles,et al. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator. , 1988, The Journal of biological chemistry.
[49] C. Hamm,et al. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. , 1988, The American journal of cardiology.
[50] L. Nelles,et al. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator. , 1988, The Journal of biological chemistry.
[51] S. Hohnloser,et al. Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase. , 1988, Klinische Wochenschrift.
[52] D. Rifkin,et al. Cell-associated plasminogen activation: regulation and physiological functions. , 1988, Annual review of cell biology.
[53] B. André,et al. Mutant and chimeric recombinant plasminogen activators. Production in eukaryotic cells and preliminary characterization. , 1987, The Journal of biological chemistry.
[54] D. Collen,et al. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator. , 1987, The Journal of biological chemistry.
[55] L. Nelles,et al. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. , 1987, The Journal of biological chemistry.
[56] K. Fujikawa,et al. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. , 1986, The Journal of biological chemistry.
[57] D. Collen,et al. Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. , 1986, The Journal of biological chemistry.
[58] M. Blaber,et al. Activation of plasminogen by pro-urokinase. I. Mechanism. , 1986, The Journal of biological chemistry.
[59] D. Collen,et al. Activation of Plasminogen by Pro-urokinase , 1986 .
[60] H. Heyneker,et al. Cloning and Expression of the Gene for Pro-urokinase in Escherichia coli , 1985, Bio/Technology.
[61] P. Verde,et al. Human urokinase gene is located on the long arm of chromosome 10. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[62] T. Sako. Overproduction of staphylokinase in Escherichia coli and its characterization. , 1985, European journal of biochemistry.
[63] K. Danø,et al. Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.
[64] D. Collen,et al. Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – II. Turnover of Natural and Recombinant Urokinase in Rabbits and Squirrel Monkeys , 1984, Thrombosis and Haemostasis.
[65] P. Verde,et al. Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[66] Z. Váli,et al. Kringles: modules specialized for protein binding , 1984, FEBS Letters.
[67] R. W. Scott,et al. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. , 1984, Journal of Biological Chemistry.
[68] L. Ossowski,et al. Modulation of plasminogen activator in rodent mammary tumors by hormones and other effectors. , 1983, Cancer research.
[69] J. Zeuthen,et al. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. , 1982, Biochemistry.
[70] L. Flohé,et al. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. , 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.
[71] Bernik Mb,et al. Plasminogen activator and proactivator (urokinase precursor) in lung cultures. , 1976 .
[72] M. Bernik,et al. Plasminogen activator and proactivator (urokinase precursor) in lung cultures. , 1976, Journal of the American Medical Women's Association.
[73] A. S. Douglas,et al. In vitro studies of staphylokinase. , 1965, Clinical science.
[74] C. Kerber,et al. EFFECTS OF FIBRINOLYTIC AGENTS AND HEPARIN ON INTRAVASCULAR CLOT LYSIS. , 1964, The American journal of physiology.
[75] J. Lewis,et al. A proteolytic enzyme system of the blood. III. Activation of dog serum profibrinolysin by staphylokinase. , 1951, The American journal of physiology.
[76] Brain Wr,et al. Mind and matter. , 1951 .
[77] C. Lack. Staphylokinase: an Activator of Plasma Protease , 1948, Nature.